The American Journal of Medicine
Volume 119, Issue 10, Supplement 1 , Pages 63-72 , October 2006

The Role of Patient-Centered Outcomes in the Course of Chronic Obstructive Pulmonary Disease: How Long-Term Studies Contribute to Our Understanding

  • Donald P. Tashkin, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Donald P. Tashkin, MD, Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, University of California–Los Angeles, 10833 Le Conte Avenue, Los Angeles, California 90095-1690.

References 

  1. Curtis JR , Patrick DL . The assessment of health status among patients with COPD . Eur Respir J Suppl . 2003;41:36s–45s
  2. Carlson DJ , Ries AL , Kaplan RM . Prediction of maximum exercise tolerance in patients with COPD . Chest . 1991;100:307–311
  3. O’Donnell DE , Webb KA . Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation . Am Rev Respir Dis . 1993;148:1351–1357
  4. Bauerle O , Chrusch CA , Younes M . Mechanisms by which COPD affects exercise tolerance . Am J Respir Crit Care Med . 1998;157:57–68
  5. Fletcher C , Peto R . The natural history of chronic airflow obstruction . BMJ . 1977;1:1645–1648
  6. Anthonisen NR , Connett JE , Kiley JP , et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study . JAMA . 1994;272:1497–1505
  7. Nishimura K , Izumi T , Tsukino M , Oga T . Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD . Chest . 2002;121:1434–1440
  8. Celli BR , Cote CG , Marin JM , et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease . N Engl J Med . 2004;350:1005–1012
  9. Tashkin D , Kesten S . Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses . Chest . 2003;123:1441–1449
  10. Rennard S , Carrera M , Agusti AG . Management of chronic obstructive pulmonary disease: are we going anywhere? . Eur Respir J . 2000;16:1035–1036
  11. Donaldson GC , Seemungal TA , Bhowmik A , Wedzicha JA . Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease . Thorax . 2002;57:847–852
  12. Casanova C , Cote C , de Torres JP , et al.  Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease . Am J Respir Crit Care Med . 2005;171:591–597
  13. Incalzi RA , Fuso L , De Rosa M , et al.  Electrocardiographic signs of chronic cor pulmonale: a negative prognostic finding in chronic obstructive pulmonary disease . Circulation . 1999;99:1600–1605
  14. Anthonisen NR , Wright EC , Hodgkin JE . Prognosis in chronic obstructive pulmonary disease . Am Rev Respir Dis . 1986;133:14–20
  15. Vestbo J . The TORCH (Towards a Revolution in COPD Health) survival study protocol . Eur Respir J . 2004;24:206–210
  16. Decramer M , Celli B , Tashkin D , et al.  Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial . Journal of Chronic Obstructive Pulmonary Diseases . 2004;1:303–312
  17. Crapo RO , Jensen RL , Hargreave FE . Airway inflammation in COPD: physiological outcome measures and induced sputum . Eur Respir J Suppl . 2003;41:19s–28s
  18. Spencer S , Jones PW . Time course of recovery of health status following an infective exacerbation of chronic bronchitis . Thorax . 2003;58:589–593
  19. Jones PW , Spencer S , Duprat-Lomon I , Sagnier PP , Wilson R . Value of measuring SGRQ at stable phase of COPD to predict the timing and deterioration associated with next exacerbation: the MOSAIC study [abstract] . Eur Respir J . 2004;24:240s
  20. Connors AF , Dawson NV , Thomas C , et al. SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)   Outcomes following acute exacerbation of severe chronic obstructive lung disease [published correction appears in Am J Respir Crit Care Med. 1997;155:386] . Am J Respir Crit Care Med . 1996;154:959–967
  21. Global Initiative for Chronic Obstructive Lung Disease (GOLD) . In: Global Strategy for the Diagnosis, Managment, and Prevention of Chronic Obstructive Pulmonary Disease—Updated 2003 . Bethesda, MD: US Dept of Health and Human Services, National Institutes of Health; 2004;
  22. Pinto-Plata VM , Cote C , Cabral H , Taylor J , Celli BR . The 6-min walk distance: change over time and value as a predictor of survival in severe COPD . Eur Respir J . 2004;23:28–33
  23. MacNee W , Calverley PM . Chronic obstructive pulmonary disease (7: management of COPD) . Thorax . 2003;58:261–265
  24. Make B , Hanania NA , ZuWallack R , et al.  The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study . Clin Ther . 2005;27:531–542
  25. Alsaeedi A , Sin DD , McAlister FA . The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials . Am J Med . 2002;113:59–65
  26. Calverley P , Pauwels R , Vestbo J , et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial . Lancet . 2003;361:449–456
  27. Mahler DA , Wire P , Horstman D , et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease . Am J Respir Crit Care Med . 2002;166:1084–1091
  28. Lung Health Study Research Group . Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease . N Engl J Med . 2000;343:1902–1909
  29. Burge PS , Calverley PM , Jones PW , Spencer S , Anderson JA , Maslen TK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial . BMJ . 2000;320:1297–1303
  30. Pauwels RA , Lofdahl CG , Laitinen LA , et al.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease . N Engl J Med . 1999;340:1948–1953
  31. Vestbo J , Sorensen T , Lange P , Brix A , Torre P , Viskum K . Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial . Lancet . 1999;353:1819–1823
  32. Szafranski W , Cukier A , Ramirez A , et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease . Eur Respir J . 2003;21:74–81
  33. Calverley PM , Boonsawat W , Cseke Z , Zhong N , Peterson S , Olsson H . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease . Eur Respir J . 2003;22:912–919
  34. Sassi-Dambron DE , Eakin EG , Ries AL , Kaplan RM . Treatment of dyspnea in COPD: a controlled clinical trial of dyspnea management strategies . Chest . 1995;107:724–729
  35. Weir DC , Bale GA , Bright P , Sherwood Burge P . A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease . Clin Exp Allergy . 1999;29(suppl 2):125–128
  36. Sin DD , McAlister FA , Man SF , Anthonisen NR . Contemporary management of chronic obstructive pulmonary disease: scientific review . JAMA . 2003;290:2301–2312
  37. Soriano JB , Kiri VA , Pride NB , Vestbo J . Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients . Am J Respir Med . 2003;2:67–74
  38. Suissa S . Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies . Am J Respir Crit Care Med . 2003;168:49–53
  39. Fan VS , Bryson CL , Curtis JR , et al.  Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis . Am J Respir Crit Care Med . 2003;168:1488–1494
  40. Soriano JB , Vestbo J , Pride NB , Kiri V , Maden C , Maier WC . Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice . Eur Respir J . 2002;20:819–825
  41. Suissa S . Inhaled steroids and mortality in COPD: bias from unaccounted immortal time . Eur Respir J . 2004;23:391–395
  42. Calverley PMA , Celli B , Ferguson G , et al.  Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study [abstract] . Eur Respir J . 2003;22:578s
  43. Casaburi R , Mahler DA , Jones PW , et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease . Eur Respir J . 2002;19:217–224
  44. Vincken W , van Noord JA , Greefhorst AP , et al. Dutch/Belgian Tiotropium Study Group   Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium . Eur Respir J . 2002;19:209–216
  45. Anzueto A , Tashkin D , Menjoge S , Kesten S . One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium . Pulm Pharmacol Ther . 2005;18:75–81
  46. Briggs DJ , Covelli H , Lapidus R , Bhattacharya S , Kesten S , Cassino C . Improved daytime spirometric efficacy of tiotropium compared with salmeterol in COPD patients [abstract] . Am J Respir Crit Care Med . 2004;169:A518
  47. Donohue JF , van Noord JA , Bateman ED , et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol . Chest . 2002;122:47–55
  48. Dusser D , Bravo ML , Iacono P . The effect of tiotropium on exacerbations and airflow in patients with COPD . Eur Respir J . 2006;27:547–555
  49. Niewoehner DE , Rice K , Cote C , et al.  Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial . Ann Intern Med . 2005;143:317–326
  50. Tashkin D , Celli B , Decramer M , Burkhart D , Kesten S , Cassino C . Prescribing patterns according to COPD treatment guidelines in patients enrolled in a global clinical setting. . 2006; Presented at the Annual Meeting of the American Thoracic Society: May 19–24,; San Diego, CA.
  51. Celli B , Decramer M , Tashkin D , et al.  Predictors of mortality in a large global COPD clinical trial. . 2006; Presented at the Annual Meeting of the American Thoracic Society; San Diego, CA.
  52. Decramer M , Tashkin D , Celli B , et al.  Predictors of exacerbations of COPD in a large global clincal trial. . 2006; Presented at the Annual Meeting of the American Thoracic Society: May 19– 24,; San Diego, CA.

PII: S0002-9343(06)00930-2

doi: 10.1016/j.amjmed.2006.08.009

The American Journal of Medicine
Volume 119, Issue 10, Supplement 1 , Pages 63-72 , October 2006

Article Tools

* Image Usage & Resolution